How Analysts Feel About GlaxoSmithKline plc (ADR) After Today’s Bullish Options Activity?

 How Analysts Feel About GlaxoSmithKline plc (ADR) After Today's Bullish Options Activity?

In today’s session GlaxoSmithKline plc (ADR) (GSK) registered an unusually high (160) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious GSK increase. With 160 contracts traded and 7044 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: GSK161118C00041000 closed last at: $0.35 or 40% up. About 2.22M shares traded hands. GlaxoSmithKline plc (ADR) (NYSE:GSK) has declined 5.44% since April 4, 2016 and is downtrending. It has underperformed by 6.53% the S&P500.

GlaxoSmithKline plc (ADR) (NYSE:GSK) Ratings Coverage

Out of 11 analysts covering GlaxoSmithKline (NYSE:GSK), 6 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 55% are positive. $50 is the highest target while $40 is the lowest. The $47.50 average target is 22.45% above today’s ($38.79) stock price. GlaxoSmithKline has been the topic of 16 analyst reports since September 8, 2015 according to StockzIntelligence Inc. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) has “Buy” rating given on Thursday, July 14 by Jefferies. The rating was upgraded by Bank of America to “Neutral” on Tuesday, September 8. The rating was upgraded by Bryan Garnier & Cie on Wednesday, January 27 to “Buy”. On Tuesday, October 20 the stock rating was upgraded by Credit Suisse to “Neutral”. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) has “Buy” rating given on Thursday, October 20 by Investec. The firm has “Overweight” rating given on Friday, September 23 by Piperjaffray. BNP Paribas upgraded the stock to “Neutral” rating in Tuesday, September 15 report. Bank of America upgraded the stock to “Buy” rating in Wednesday, December 9 report. The firm has “Neutral” rating by JP Morgan given on Monday, October 12. As per Friday, August 12, the company rating was maintained by Argus Research.

According to Zacks Investment Research, “GlaxoSmithKline is one of the world’s leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.”

GlaxoSmithKline plc is a healthcare company. The company has a market cap of $93.19 billion. The Firm is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. It has a 264.26 P/E ratio. The Company’s divisions include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

GSK Company Profile

GlaxoSmithKline plc (GSK), incorporated on December 6, 1999, is a healthcare company. The Firm is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company’s divisions include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

More news for GlaxoSmithKline plc (ADR) (NYSE:GSK) were recently published by: Businessfinancenews.com, which released: “GlaxoSmithKline plc (ADR) Earning Release; Here’s What to Expect” on July 26, 2016. Businessfinancenews.com‘s article titled: “GlaxoSmithKline plc (ADR) Moves Ahead in COPD Treatment” and published on May 26, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags:

Related posts

Leave a Comment